The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InMatricelf (TASE: MTLF) has announced a strategic collaboration with Sheba Medical Center to support its inaugural first-in-human clinical trial. The partnership focuses on advancing regenerative medicine therapies specifically designed for spinal cord injuries. The clinical program involves the development of autologous engineered neural tissue, a cutting-edge approach in the biotechnology sector. By collaborating with Sheba Medical Center, which is ranked 7th globally by Newsweek, Matricelf gains access to world-class clinical infrastructure and expertise. This milestone is expected to significantly reduce execution risks as the company transitions into the critical clinical phase. Investors view this move as a major step forward in validating Matricelf’s technology and its potential for future commercialization.